Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

Luca Gianni; Anna Lladó; Giulia Bianchi; Javier Cortes; Pirkko-Liisa Kellokumpu-Lehtinen; David A Cameron; David Miles; Stefania Salvagni; Andrew Wardley; Jean-Charles Goeminne; Veronica Hersberger; José Baselga

doi:10.1200/JCO.2009.24.1661

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

Luca Gianni, Anna Lladó, Giulia Bianchi, Javier Cortes, Pirkko-Liisa Kellokumpu-Lehtinen, David A Cameron, David Miles, Stefania Salvagni, Andrew Wardley, Jean-Charles Goeminne, Veronica Hersberger, José Baselga

Research output: Contribution to journal › Article › peer-review

Abstract

Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.

Original language	English
Pages (from-to)	1131-7
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	28
Issue number	7
DOIs	https://doi.org/10.1200/JCO.2009.24.1661
Publication status	Published - 2010

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antibodies, Monoclonal
Breast Neoplasms
Dimerization
Female
Humans
Middle Aged
Neoplasm Metastasis
Receptor, erbB-2
Ventricular Function, Left

Access to Document

10.1200/JCO.2009.24.1661

Fingerprint

Dive into the research topics of 'Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer'. Together they form a unique fingerprint.

Cite this

Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., Hersberger, V., & Baselga, J. (2010). Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology, 28(7), 1131-7. https://doi.org/10.1200/JCO.2009.24.1661

Gianni, Luca ; Lladó, Anna ; Bianchi, Giulia et al. / Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 7. pp. 1131-7.

@article{01d2073a0c9a481694c3bedf4df523f4,

title = "Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer",

abstract = "Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Breast Neoplasms, Dimerization, Female, Humans, Middle Aged, Neoplasm Metastasis, Receptor, erbB-2, Ventricular Function, Left",

author = "Luca Gianni and Anna Llad{\'o} and Giulia Bianchi and Javier Cortes and Pirkko-Liisa Kellokumpu-Lehtinen and Cameron, \{David A\} and David Miles and Stefania Salvagni and Andrew Wardley and Jean-Charles Goeminne and Veronica Hersberger and Jos{\'e} Baselga",

year = "2010",

doi = "10.1200/JCO.2009.24.1661",

language = "English",

volume = "28",

pages = "1131--7",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

Gianni, L, Lladó, A, Bianchi, G, Cortes, J, Kellokumpu-Lehtinen, P-L, Cameron, DA, Miles, D, Salvagni, S, Wardley, A, Goeminne, J-C, Hersberger, V & Baselga, J 2010, 'Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer', Journal of Clinical Oncology, vol. 28, no. 7, pp. 1131-7. https://doi.org/10.1200/JCO.2009.24.1661

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. / Gianni, Luca; Lladó, Anna; Bianchi, Giulia et al.
In: Journal of Clinical Oncology, Vol. 28, No. 7, 2010, p. 1131-7.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

AU - Gianni, Luca

AU - Lladó, Anna

AU - Bianchi, Giulia

AU - Cortes, Javier

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Cameron, David A

AU - Miles, David

AU - Salvagni, Stefania

AU - Wardley, Andrew

AU - Goeminne, Jean-Charles

AU - Hersberger, Veronica

AU - Baselga, José

PY - 2010

Y1 - 2010

N2 - Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.

AB - Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Breast Neoplasms

KW - Dimerization

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Receptor, erbB-2

KW - Ventricular Function, Left

U2 - 10.1200/JCO.2009.24.1661

DO - 10.1200/JCO.2009.24.1661

M3 - Article

C2 - 20124183

SN - 0732-183X

VL - 28

SP - 1131

EP - 1137

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 7

ER -

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology. 2010;28(7):1131-7. doi: 10.1200/JCO.2009.24.1661